SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| ENEVOM 125 MG CAPSULE | 125 mg | Capsule, hard · Oral use | 1 Blister | SAR 79.05 | NCE · Prescription | MS Pharma Saudi (MSPS) | Valid |
| ENEVOM 80 MG CAPSULE | 80 mg | Capsule, hard · Oral use | 1 Blister | SAR 79.05 | NCE · Prescription | MS Pharma Saudi (MSPS) | Valid |
Indications — CHI Daman Drug Formulary
NAUSEA AND VOMITING IN CANCER; POLYCYTHEMIA VERA - PRURITUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| EMEND | 80MG; 125MG | capsule · oral | MSD | Prescription | 26 Mar 2003 |
| APREPITANT | 40MG; 80MG; 125MG | capsule · oral | SANDOZ | Prescription | 24 Sep 2012 |
| APREPITANT | 40MG; 80MG; 125MG | capsule · oral | GLENMARK SPECLT | Prescription | 12 Oct 2017 |
| CINVANTI | 130MG/18ML (7.2MG/ML) | emulsion · intravenous | HERON THERAPS INC | Prescription | 9 Nov 2017 |
| APREPITANT | 40MG; 80MG; 125MG | capsule · oral | TORRENT | Prescription | 21 Oct 2020 |
| APONVIE | 32MG/4.4ML (7.2MG/ML) | emulsion · intravenous | HERON THERAPS INC | Prescription | 16 Sep 2022 |
| APREPITANT | 130MG/18ML (7.2MG/ML) | emulsion · intravenous | AZURITY | Prescription | 16 Jun 2026 |
| EMEND | 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | MSD | Discontinued | 26 Mar 2003 |
| EMEND | 125MG/KIT | for suspension · oral | MSD MERCK CO | Discontinued | 17 Dec 2015 |
| APREPITANT | 32MG/4.4ML (7.2MG/ML) | emulsion · intravenous | MYLAN | Discontinued | 5 Mar 2026 |
EMA European Union — centrally authorised medicines
Emend Merck Sharp & Dohme B.V. · Authorised · authorised 11 Nov 2003 · ATC A04AD12
Therapeutic indication (EMA)
Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics). Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| EMEND | 02298791 | 80 MG | CAPSULE · ORAL | MERCK CANADA INC |
| EMEND | 02298805 | 125 MG | CAPSULE · ORAL | MERCK CANADA INC |
| EMEND TRI-PACK | 02298813 | 125 MG; 80 MG | CAPSULE; KIT · ORAL | MERCK CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | APREPITANT 125 MG CAPSULE | $114.04399 | per EA | 23 Sep 2026 |
| US NADAC | APREPITANT 125-80-80 MG PACK | $85.017 | per EA | 23 Sep 2026 |
| US NADAC | APREPITANT 40 MG CAPSULE | $46.42062 | per EA | 23 Sep 2026 |
| US NADAC | APREPITANT 80 MG CAPSULE | $76.35243 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Aprepitant 125mg capsules | £79.03 | 5 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Aprepitant 125mg capsules and Aprepitant 80mg capsules | £47.71 | 3 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Aprepitant 80mg capsules | £31.61 | 2 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 17.2. Antiemetic medicines · complementary
Nausea or vomiting
Oral > Liquid: 125 mg powder for oral suspension (in sachet) | Oral > Solid > capsule: 80 mg (EML); 125 mg (EML); 165 mg (EML)
Safety signals and safety-related labeling changes
- US FDA 14 Nov 2019 EMEND — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 Nov 2019 EMEND — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Oct 2019 CINVANTI — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
All safety entries for aprepitant →
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.